Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC

In this week's instalment of the VJOncology podcast, we examine the rapidly evolving treatment landscape of advanced non-small cell lung cancer, drawing on expert insights from ELCC 2026. This episode spans the breadth of precision oncology in NSCLC: from the clinical challenges of rare actionable alterations and emerging targeted agents, to the growing complexity of first-line treatment sequencing, and the arrival of a promising new immunotherapy class in thoracic oncology. Leading clinicians and researchers from the Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, and Lausanne University Hospital discuss BRAF non-V600E mutations, KRAS G12C, HER2-mutant disease, EGFR exon 20 insertions, amivantamab-based combinations, and the evolving role of bispecific T-cell engagers in NSCLC and mesothelioma. This episode provides actionable insight for clinicians navigating an increasingly crowded and competitive treatment landscape in advanced NSCLC.